Dosimetric Evaluation of MapCHECK in MapPHAN for Conformal Arc SABR Quality Assurance
Nathan I. N. Henry, Christopher M. Thompson, Steven Marsh, Jack D. Aylward

TL;DR
This study evaluates the effectiveness of MapCHECK in MapPHAN for quality assurance in conformal arc SABR, demonstrating its sensitivity and specificity in detecting MLC and isocentre errors through gamma analysis and ROC curves.
Contribution
It provides a detailed dosimetric assessment of MapCHECK in MapPHAN for SABR QA, establishing optimal gamma criteria for error detection.
Findings
MapCHECK in MapPHAN shows high sensitivity and specificity for error detection.
Optimal gamma criteria identified as 5%/1mm with 95% tolerance and 2%/1mm with 90% tolerance.
Effective for QA of conformal arc SABR plans.
Abstract
This study investigates the sensitivity and specificity of the MapCHECK phantom housed in MapPHAN to errors in conformal arc Stereotactic Ablative Body Radiotherapy (SABR). A specific focus is applied to Organ At Risk (OAR) dosimetry. Multi-Leaf Collimator (MLC) class shift errors up to 2 mm, and isocentre shift errors of up to 1 mm, were introduced to 23 simulated 6 MV X-ray conformal arc lung SABR plans in Raystation. Overall, 198 plans were delivered on a Varian Clinac iX linear accelerator to an in-house modified MapCHECK in MapPHAN. Gamma analysis was used to compare the MapCHECK measurements to the simulated Raystation plans. Receiver Operating Characteristic (ROC) curves were generated from these results to determine the sensitivity and specificity of the measurement technique to the introduced errors. For MapCHECK in MapPHAN, a combination of 5%/1 mm with 95% gamma tolerance and…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsAdvanced Radiotherapy Techniques · Breast Cancer Treatment Studies · Advances in Oncology and Radiotherapy
